Recent data reveal an important role for B cells in the pathogenesis of chronic GVHD (cGVHD).
Introduction
Chronic GVHD is a significant cause of non-relapse mortality in patients after allogeneic hematopoietic stem cell transplant (HSCT). Treatment options remain inadequate because the immune mechanisms underlying the disease are ill defined. While T lymphocytes have an established role in the pathogenesis of cGVHD, 1 murine models and clinical trials implicate an emerging role for B cells in disease pathogenesis (reviewed in 2 ) . In mouse models, depletion of donor B cells in the graft was shown to reduce the incidence of GVHD. 3 Subsequently, B cells were found to infiltrate sites of fibrosis in mice with cGVHD, and genetic inhibition of donor B
cell IgG secretion was shown to prevent cGVHD. 4 In transplant patients, the presence of antibodies specific for host minor histocompatibility antigens (miHA) was found to be associated with cGVHD. 5, 6 In addition, several phase I-II trials of B cell-directed therapy for steroidrefractory cGVHD demonstrated clinical efficacy. [7] [8] [9] [10] [11] [12] Taken together, this work provides compelling evidence for the importance of B cells in cGVHD, but the mechanisms that promote and sustain B cell involvement in pathogenesis have not been elucidated.
Patients with cGVHD have altered B cell homeostasis. [13] [14] [15] [16] B cell reconstitution is delayed, and plasma B cell-activating factor (BAFF) levels are elevated, resulting in a significantly increased BAFF/B cell ratio. 17 In contrast, cGVHD patients who demonstrate clinical improvement and positive response to treatment have robust recovery of the peripheral naïve B cell pool. 13, 18, 19 These findings are consistent with previous demonstration in murine models that physiological BAFF/B cell ratios result in deletion of autoreactive B cells. 20 In contrast, when BAFF is in excess, peripheral tolerance is lost and autoreactive B-cells survive. 21 Whether excess BAFF promotes potentially allo or autoreactive B cell populations in cGVHD remains unknown.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From BAFF increases the survival of both murine and human splenic B cells, and has been shown to increase the metabolic state of murine B cells. [22] [23] [24] [25] [26] Addition of BAFF caused increases in mouse B cell size, cellular protein content, and alterations in gene transcriptional programs associated with glycolysis and survival. 23 B and T cells deprived of physiological growth factor support lose volume and die unless rescued with exogenous growth factors or the provision of anti-apoptotic molecules. 27, 28 The loss of B cell volume associated with growth factor deprivation can be overcome by exogenous BAFF. 24 While BAFF signaling in human nonneoplastic B cells remains unexplored, recent studies have elucidated several pathways involved in BAFF-mediated effects on B cell metabolic activity and survival. Signaling through the AKT pathway has an established role in the maintenance of B cell growth and survival (reviewed in 29 ), and BAFF has been shown to activate AKT in murine B cells. 23 Additionally, BAFF treatment activates extracellular signal-regulated kinase (ERK). 30 which directly enhances murine B cell survival by counteracting the proapoptotic BH3-only protein Bim. 30 Bim is crucial for the apoptosis of hematopoietic cells, including B cells, 31 and undergoes ubiquitination and degradation by the proteasome after phosphorylation by ERK. 32, 33 Consequently, autoreactive B cells deficient in Bim are protected from apoptosis through a mechanism involving BAFF. 20, 34, 35 Given these data, we hypothesized that B cells in patients with cGVHD are in a state of constant activation. We aimed to determine whether increased BAFF signaling elevated the metabolic activity of B cells from patients with cGVHD and promoted their survival. Our data show that peripheral B cells purified from patients with cGVHD are in a heightened metabolic state and are resistant to apoptosis. Exogenous BAFF treatment further increased B-cell size and survival. Furthermore, B cells from patients with cGVHD exhibited ongoing signaling through the AKT and ERK pathway, and this was associated with decreased levels of Bim protein. These
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From data suggest a compelling mechanistic link between increased BAFF levels, aberrant survival of B cells, and disease pathogenesis in patients with cGVHD. Institutes of Health cGVHD consensus criteria) and confirmed by a physician blinded to our experimental data. Sixteen patients were classified as having active cGVHD at time of specimen collection. Thirty-five patients were classified as not having cGVHD at time of specimen collection. Patients without cGVHD at date of collection included patients who may have previously had cGVHD (20 patients, 57%) in addition to patients who never developed cGVHD (15 patients, 43%). Importantly, there were no significant differences in clinical characteristics or immune suppressive treatment between patients with resolved disease and patients who never 
Materials and Methods

Patient characteristics
Purification of B cell subsets
Large volume leukapheresis products were obtained from 3 patients with chronic GVHD. The PBMCs were isolated, as described in the previous section, and viably frozen. Total B cells were initially purified by negative selection using the human B cell isolation kit II (Miltenyi Biotech, Auburn, CA) to ≥ 98% purity as measured by CD19 expression according to the manufacturer's 
Protein content and flow cytometric analysis of cell size
The cellular protein content of purified B cells was quantified using the BCA Protein Assay protein content was analyzed in 20 patients and was significantly increased in patients with cGVHD compared to patients without cGVHD (Figure 1a) . B cells from patients with cGVHD
Statistical methods
were also significantly increased in size ex vivo compared to B cells from patients without cGVHD after a 24-hour rest period (Figure 1b) . While the increase in protein content and cell size may correlate with disease onset and severity, it is difficult to ascertain in this study due to limited sample numbers.
Using IgG production as a surrogate for B cell activation, we previously found that the CD27 + B cell subset was activated in patients with cGVHD. 14 These cells constitutively produced IgG ex vivo, something that does not occur in ex vivo isolated CD27 + B cells from allogeneic HCST patients without cGVHD or healthy donors. 14 We examined whether activated CD27 + B cells had increased size compared to the CD27 -B cell subset in patients with cGVHD.
Analysis of these purified subsets requires large-volume leukapheresis samples, therefore, limiting our patient number to the 3 patients with cGVHD that consented to collection. We found that CD27 + B cells were significantly increased in size compared to CD27 -B cells (Figure 2a ).
This CD27 + B cell population can be further subdivided by the expression of IgD and CD38. 26, 36 Of these, the pre-germinal center (GC) B (Figure 3a) and the activated CD27 + B cell subset (Figure 3b ).
These data suggest that BAFF in patients with cGVHD may be responsible for amplifying their metabolic state, as measured by cell size. (Figure 4b) . These data taken together suggest that B cells in patients with cGVHD are activated and resistant to apoptosis. 
Signaling associated with metabolic activity and survival is increased in B cells from patients with cGVHD. In murine B cells, BAFF activates AKT by phosphorylation, resulting in
an increase in metabolic activity and protein synthesis. 23, 24 In addition, BAFF controls murine B cell survival by triggering the ERK pathway resulting in ubiquitination and degradation of the proapoptotic molecule Bim. 30 To begin to determine the molecular mechanisms underlying BAFF-mediated modulation of metabolic activity and apoptosis in B cells from patients with cGVHD, we tested whether the ERK and AKT pathways were activated in B cells freshly (Figure 6b) . As BAFF-driven activation of ERK and subsequent decrease in Bim blocks B cell apoptosis, 30 we analyzed the expression of the three known isoforms of Bim (Bim EL , Bim L , and Bim S ) in patients with cGVHD. While all three isoforms induce apoptosis, Bim S appears to be the most potent. 38 As shown in Figure 6c , Patients with cGVHD have elevated BAFF/B cell ratios 14 coupled with abnormal B cell homeostasis. [13] [14] [15] [16] The present study, the first to show that BAFF alters metabolic activity and survival of B cells from patients with cGVHD, provides data that are consistent with murine models showing that BAFF can control both metabolism and apoptosis in B cells in other diseases. 23, 30 We found both increased total protein content and increased size of B cells and CD27 + B cells subsets (Figure 1 and Figure 2) . Size heterogeneity within the CD27 + pre-GC population was also seen (Figure 2b) , potentially related to non-synchronous cell cycle states or to the presence of additional subpopulations within the pre-GC subset. BAFF mediates transcription and translation of genes required for cell cycle progression in murine B cells, 41 It is possible that BAFF-mediated in vivo activation leads to a reduced dependence on growth factor mediated (i.e., BAFF) survival ex vivo. Taken together, these data suggest that BAFF: (1) elevates the metabolic activity of both CD27 -and CD27 + B cell subsets in patients with cGVHD; and (2) is an important survival factor for the CD27 -B cell subset.
BAFF-induced signaling cascades associated with murine B cell metabolic activity and survival are triggered in patients with cGVHD. AKT activation is directly associated with metabolic state of murine B cells, 23 42 Patients with cGVHD have a lower frequency of T regs 43, 44 , due in part to increased susceptibility to Fas-mediated apoptosis. 45 The alterations in T reg and B cell homeostasis in patients with cGVHD, coupled with our current study, suggest further studies on T-B cell interactions in the pathophysiology of cGVHD are necessary.
BAFF is capable of amplifying B cell responses to antigen. 23, 46 Whether the increased BAFF and altered B cell signaling in patients with cGVHD amplifies the response to the numerous allo-and autoantigens present in the post-HSCT setting warrants further study. Taken together, our data suggest a mechanistic link between elevated BAFF levels, improved metabolic activity and survival of B cells, and disease pathogenesis in patients with cGVHD. Additionally, our data suggest novel therapeutic targets in human cGVHD.
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